| 2 |
2
청구항 1에 있어서, 상기 화학식 1에서 R1은 페닐, 벤질, 디메틸사이클로헥센, 메톡시페닐 또는 (트리플루오로메틸)페닐이고, R2 및 R3 은 각각 동일하거나 다르며, 수소, 디메틸페닐, 에틸페닐, 메틸-1H-인다졸-4-일, 벤조[d]티아졸-2-일, 페닐티아졸-2-일, 메틸피페리딘-4-일 또는 피리딘-4-일이고, 또는 R2 와 R3 가 서로 결합하여 5,6-디하이드로-[1,2,4]트리아졸로[4,3-a]피라진-7(8H)인 것이고, R4는 벤조[c][1,2,5]티아디아졸, 벤조[c][1,2,5]옥사디아졸, 메틸-1H-인다졸, 벤조[d][1,3]디옥솔, 메톡시페닐 또는 메틸페틸인 것을 특징으로 하는 암질환 예방 또는 치료용 약학조성물
|
| 3 |
3
청구항 1에 있어서, 화학식 1로 표시되는 화합물, 이의 입체이성질체 또는 이의 약제학적으로 허용가능한 염은 α-[(2,1,3-벤조티아디아졸-4-일설포닐)아미노]-N-(3,5-디메틸페닐)-벤젠아세트아미드{α-[(2,1,3-benzothiadiazol-4-ylsulfonyl)amino]-N-(3,5-dimethylphenyl)-benzeneacetamide}, α-[(2,1,3-벤조티아디아졸-4-일설포닐)아미노]-N-(3-에틸페닐)-벤젠아세트아미드{α-[(2,1,3-benzothiadiazol-4-ylsulfonyl)amino]-N-(3-ethylphenyl)-benzeneacetamide}, 2-(벤조[c][1,2,5]티아디아졸-4-설폰아미도)-N-(1-메틸-1H-인다졸-4-일)-2-페닐아세트아미드{2-(benzo[c][1,2,5]thiadiazole-4-sulfonamido)-N-(1-methyl-1H-indazol-4-yl)-2-phenylacetamide}, 2-(벤조[c][1,2,5]옥사디아졸-4-설폰아미도)-N-(1-메틸-1H-인다졸-4-일)-2-페닐아세트아미드{2-(benzo[c][1,2,5]oxadiazole-4-sulfonamido)-N-(1-methyl-1H-indazol-4-yl)-2-phenylacetamide}, 2-(벤조[c][1,2,5]티아디아졸-4-설폰아미도)-N-(벤조[d]티아졸-2-일)-2-페닐아세트아미드{2-(benzo[c][1,2,5]thiadiazole-4-sulfonamido)-N-(benzo[d]thiazol-2-yl)-2-phenylacetamide}, 2-(1-메틸-1H-인다졸-7-설폰아미도)-2-페닐-N-(4-페닐티아졸-2-일)아세트아미드{2-(1-methyl-1H-indazol-7-sulfonamido)-2-phenyl-N-(4-phenylthiazol-2-yl)acetamide}, 2-(벤조[c][1,2,5]옥사디아졸-4-설폰아미도)-2-(3,3-디메틸사이클로헥-1-엔-1-일)-N-(1-메틸피페리딘-4-일)아세트아미드{2-(benzo[c][1,2,5]oxadiazole-4-sulfonamido)-2-(3,3-dimethylcyclohex-1-en-1-yl)-N-(1-methylpiperidin-4-yl)acetamide}, 2-(벤조[c][1,3]디옥솔-5-설폰아미도)-2-(4-메톡시페닐)-N-(피리딘-4-일)아세트아미드{2-(benzo[d][1,3]dioxole-5-sulfonamido)-2-(4-methoxyphenyl)-N-(pyridin-4-yl)acetamide}, 2-(4-메톡시페닐설폰아미도)-N-(피리딘-4-일)-2-(4-(트리플루오로메틸)페닐)아세트아미드{2-(4-methoxyphenylsulfonamido)-N-(pyridin-4-yl)-2-(4-(trifluoromethyl)phenyl)acetamide}, N-(2-(3-메틸-5,6-디하이드로-[1,2,4]트리아졸[4,3-a]피라진-7(8H)-일)-2-옥소-1-페닐에틸)벤조[c][1,2,5]티아디아졸-4-설폰아미드{N-(2-(3-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-2-oxo-1-phenylethyl)benzo[c][1,2,5]thiadiazole-4-sulfonamide}, 4-메틸-N-(2-(3-메틸-5,6-디하이드로-[1,2,4]트리아졸[4,3-a]피라진-7(8H)-일)-2-옥소-1-(4-(트리플루오로메틸)페닐)에틸)벤젠설폰아미드{4-methyl-N-(2-(3-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-2-oxo-1-(4-(trifluoromethyl)phenyl)ethyl)benzenesulfonamide} 및 N-(1-(3-메틸-5,6-디하이드로-[1,2,4]트리아졸[4,3-a]피라진-7(8H)-일)-1-옥소-3-페닐프로판-2-일)벤조[c][1,2,5]옥사디아졸-4-설폰아미드{N-(1-(3-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-1-oxo-3-phenylpropan-2-yl)benzo[c][1,2,5]oxadiazole-4-sulfonamide}로 이루어진 군에서 선택되는 것을 특징으로 하는 암질환 예방 또는 치료용 약학조성물
|
